ProMIS Neurosciences Inc., a clinical-stage biotechnology firm focused on developing therapeutic antibodies for neurodegenerative diseases, has filed a prospectus with the U.S. Securities and Exchange Commission regarding a registered direct offering. The company plans to raise approximately $0.8 million from an existing healthcare-focused institutional investor. The funds will be used to advance the clinical development of PMN310, ProMIS's leading therapeutic candidate, as well as for working capital and general corporate purposes. The offering involves the issuance and sale of pre-funded warrants to purchase 984,736 common shares at a price of $0.8124 per share. These warrants are exercisable at a nominal price of $0.0001 per share and can be activated at any time until fully exercised. The closing of the offering is anticipated on or around July 24, 2025, pending customary closing conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。